Skip to main content
Joseph Pagano, MD, Infectious Disease, Chapel Hill, NC

Joseph S Pagano MD Prof.

Healthcare Associated Infections, Transplant/Immunocompromised States


Physician

Join to View Full Profile
  • 101 Manning DrChapel Hill, NC 27514

  • Phone+1 919-966-4996

  • Fax+1 919-843-5515

Dr. Pagano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1960 - 1961
  • Boston University Medical Center
    Boston University Medical CenterInternship, Internal Medicine, 1957 - 1958
  • Yale School of Medicine
    Yale School of MedicineClass of 1957

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1965 - 2020

Awards, Honors, & Recognition

  • Elected Member Institute of Medicine, 1998

Publications & Presentations

PubMed

Journal Articles

  • Expression of Interferon Regulatory Factor 7 Correlates with the Expression of Epstein–Barr Virus Latent Membrane Protein 1 and Cervical Lymph Node Metastasis in Nasop...  
    Joseph Pagano, MD, Pathology International

Grant Support

  • Cellular And Viral Regulation Of EBV Latency: Implication Of Ubiquitin-Editing ENNational Cancer Institute2011
  • Basic Mechanisms Of Viral And Chemical CarcinogenesisNational Cancer Institute1985–2011
  • New EBV Therapies For Treating MalignanciesNational Heart, Lung, And Blood Institute2005–2009
  • Cellular And Viral Regulation Of Type III EBV LatencyNational Cancer Institute2005–2009
  • Interferon Regulatory Factor 7 EBV Latency &OncogenesisNational Institute Of Allergy And Infectious Diseases2003
  • EBV Vectors For Targeted Gene Therapy Of B-LymphomasNational Heart, Lung, And Blood Institute2000–2003
  • Cellular Regulation Of Type III EBV LatencyNational Cancer Institute1999–2002
  • Interferon Regulatory Factors Cell Cycle And EBV LatencyNational Institute Of Allergy And Infectious Diseases1998–2002
  • Major Programs For Cancer Center SupportNational Cancer Institute1997–2002
  • Core--Developmental ProjectsNational Cancer Institute1997–2002
  • RAZ, A Transdominant Repressor, Modulates EBV ReactivationNational Cancer Institute1994–1999
  • Herpesviral Oncogenesis, Latency And ReactivationNational Cancer Institute1994–1999
  • Lineberger Cancer Control Education ProgramNational Cancer Institute1992–1996
  • Cancer Center Support GrantNational Cancer Institute1985–1996
  • CancerNational Cancer Institute1994
  • Expression And Regulation Of EBV DNA PolymeraseNational Cancer Institute1992–1994
  • Viral Oncogenesis And LatencyNational Cancer Institute1989–1994
  • Expansion Of The Lineberger Comprehensive Cancer CenterNational Cancer Institute1992–1993
  • Oncogenic Potential Of EBV Latency And Transforming GeneNational Cancer Institute1992
  • Fifth International Symposium On EBV And Associated DISNational Cancer Institute1992
  • Antiviral Drugs And Epstein-Barr Virus Infection StatesNational Institute Of Allergy And Infectious Diseases1991–1992
  • HTLV-III, Antiviral Drugs &Ebv In B CellsNational Institute Of Allergy And Infectious Diseases1986–1988
  • DNA Virus Genomes, Oncogenesis And LatencyNational Cancer Institute1985–1988
  • Acyclovir And Other Drug Inhibition Of EBV ReplicationNational Institute Of Allergy And Infectious Diseases1985–1987

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: